Daigo Kenji, Inforzato Antonio, Barajon Isabella, Garlanda Cecilia, Bottazzi Barbara, Meri Seppo, Mantovani Alberto
Department of Inflammation and Immunology, Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
Department of Medical Biotechnologies and Translational Medicine, University of Milan, Italy.
Immunol Rev. 2016 Nov;274(1):202-217. doi: 10.1111/imr.12476.
Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.
体液液相模式识别分子(PRMs)是天然免疫激活和调节的关键组成部分。体液PRMs种类多样。我们将长五聚体蛋白3(PTX3)作为液相PRMs的典型例子进行重点研究。PTX3作为抗体的功能前体,在小鼠和人类抵抗特定微生物以及炎症调节中发挥着不可替代的作用。该分子与补体成分相互作用,从而调节补体激活。特别是,PTX3在临床前模型和特定人类肿瘤中作为一种外在的肿瘤抑制因子,调节补体驱动的巨噬细胞介导的肿瘤进展。多年来收集的证据表明,PTX3是人类的一种生物标志物和潜在治疗药物,并为将该分子转化应用于临床铺平了道路。